Bioaffinity Technologies, Inc. (BIAF) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bioaffinity Technologies, Inc. on March 13, 2024, reporting events that occurred on March 8, 2024. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in San Antonio, Texas. Its common stock and tradeable warrants trade on The Nasdaq Stock Market LLC under the symbols BIAF and BIAFW, respectively.
Key Financial Metrics and Capital Structure
The filing details a capital raise transaction rather than operational financial results. The Company issued 1,600,000 shares of Common Stock in a registered direct offering and 1,600,000 Common Warrants in a concurrent private placement. The Common Warrants have an exercise price of $1.64. The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period.
Material Changes and Dilutive Adjustments
The issuance of the new shares and warrants constituted a "Dilutive Issuance" because the effective price per share was less than the exercise price of the Company's existing IPO Warrants (Tradeable and Non-Tradeable). Consequently, the exercise price of the existing IPO Warrants was reduced to $3.0625 per share. Additionally, the number of shares underlying the IPO Warrants was adjusted using a formula based on the prior exercise price and the new exercise price of $3.0625.
Outlook, Risks, and Management Commentary
Management commentary is limited to the execution of the Securities Purchase Agreement and the resulting adjustments to warrant terms. The filing does not contain forward-looking guidance, specific risk factors beyond the dilution mechanics, or discussion of unusual items. The primary impact is the dilution of existing warrant holders and the adjustment of their exercise terms.
Key Facts for Investor Verification
- Transaction Date: March 8, 2024.
- Shares Issued: 1,600,000 shares of Common Stock.
- Warrants Issued: 1,600,000 Common Warrants with an exercise price of $1.64.
- Warrant Adjustment: Existing IPO Warrant exercise price reduced to $3.0625 per share.
- Warrant Quantity Adjustment: The number of shares underlying existing IPO Warrants was recalculated based on the price adjustment formula.
- Missing Data: The filing does not disclose the total gross proceeds raised or the specific effective price per share of the new offering.